DonSON: A Potential Drug Target for Neurological Disorders (G29980)

Target Name: DONSON

NCBI ID: G29980

DONSON

DonSON: A Potential Drug Target for Neurological Disorders

DonSON (MIMIS), a protein that is expressed in the brain, has been identified as a potential drug target (or biomarker) for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases.

DonSON is a transmembrane protein that is expressed in the brain and is involved in the regulation of various cellular processes, including cell signaling, neurotransmitter release, and synaptic plasticity. It is a key regulator of the microtubules that organize brain cells and is thought to play a role in the development and progression of neurodegenerative diseases.

Studies have shown that DonSON is involved in the regulation of neurotransmitter release from neurons, which is critical for the function and survival of brain cells. It has been shown to play a role in the regulation of dopamine release, a neurotransmitter that is involved in motor movement, emotion, and other functions.

In addition to its role in neurotransmitter regulation, DonSON is also involved in the regulation of synaptic plasticity, which is the ability of brain cells to change and adapt over time. This is important for the formation and maintenance of neural connections, which are critical for the development and function of the brain.

DonSON has also been shown to be involved in the regulation of cell signaling, which is the process by which cells communicate with one another and coordinate their activities. This is important for the regulation of cellular processes that are critical for the development and progression of neurodegenerative diseases.

The identification of DonSON as a potential drug target is based on its involvement in the regulation of various cellular processes that are involved in the development and progression of neurodegenerative diseases. The development of DonSON-targeted therapies has the potential to treat a wide range of neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases.

In conclusion, DonSON is a protein that is expressed in the brain and is involved in the regulation of various cellular processes that are critical for the development and progression of neurodegenerative diseases. Its potential as a drug target makes it an attractive target for the development of new therapies for the treatment of these disorders. Further research is needed to fully understand the role of DonSON in the development and progression of neurodegenerative diseases and to develop effective therapies that target it.

Protein Name: DNA Replication Fork Stabilization Factor DONSON

Functions: Replisome component that maintains genome stability by protecting stalled or damaged replication forks. After the induction of replication stress, required for the stabilization of stalled replication forks, the efficient activation of the intra-S-phase and G/2M cell-cycle checkpoints and the maintenance of genome stability

The "DONSON Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DONSON comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets